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A B S T R A C T
Background
Non-infectious uveitis describes a heterogenous group of ocular disorders characterised by intraocular inflammation in the absence
of infection. Uveitis is a leading cause of visual loss, most commonly due to uveitic macular oedema (UMO). Treatment is aimed at
reducing disease activity by suppression of the intraocular inflammatory response. In the case of macular oedema, the aim is to restore
macular architecture as quickly as possible, in order to prevent irreversible photoreceptor damage in this area. Acute exacerbations are
typically managed with corticosteroids, which may be administered topically, locally or systemically. Whilst these are often rapidly
effective in achieving disease control, long-term use is associated with significant local and systemic side effects, and ’steroid sparing
agents’ are typically used to achieve prolonged control in severe or recalcitrant disease. Anti-tumour necrosis factor (TNF) drugs block
a critical cytokine in the inflammatory signalling process, and have emerged as effective steroid-sparing immunomodulatory agents in
a wide range of non-ocular conditions. There is mechanistic data to suggest that they may provide a more targeted approach to disease
control in UMO than other agents, but to date, these agents have predominantly been used ’off label’ as the majority are not licensed
for ocular use. This review aims to summarise the available literature reporting the use of anti-TNF therapy in UMO, thus developing
the evidence-base on which to make future treatment decisions and develop clinical guidelines in this area.
Objectives
To assess the efficacy of anti-TNF therapy in treatment of UMO.
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Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 2), which contains the Cochrane Eyes and
Vision Trials Register; Ovid MEDLINE; Ovid Embase; LILACS; Web of Science Conference Proceedings Citation Index- Science
(CPCI-S); System for Information on Grey Literature in Europe (OpenGrey); the ISRCTN registry; ClinicalTrials.gov and the WHO
ICTRP. The date of the search was 29 March 2018.
Selection criteria
We planned to include all relevant randomised controlled trials assessing the use of anti-TNF agents in treatment of UMO. No limits
were applied to participant age, gender or ethnicity. The primary comparisons of this review were: anti-TNF versus no treatment or
placebo; anti-TNF versus another pharmacological agent; comparison of different anti-TNF drugs; comparison of different doses and
routes of administration of the same anti-TNF drug. The primary outcome measure that we assessed for this review was best-corrected
visual acuity (BCVA) in the treated eye. Secondary outcome measures were anatomical macular change, clinical estimation of vitreous
haze and health-related quality of life.
Data collection and analysis
Two review authors independently screened titles and abstracts retrieved through the database searches. We retrieved full-text reports
of studies categorised as ’unsure’ or ’include’ after we had reviewed the abstracts. Two review authors independently reviewed each full-
text report for eligibility. We resolved discrepancies through discussion.
Main results
We identified no completed or ongoing trial that was eligible for this Cochrane Review.
Authors’ conclusions
Our review did not identify any evidence from randomised controlled trials for or against the role of anti-TNF agents in themanagement
of UMO. Although there are a number of high-quality randomised controlled trials that demonstrate the efficacy of anti-TNF agents in
preventing recurrence of inflammation in uveitis, the reported study outcomes do not include changes in UMO. As a result, there were
insufficient data to conclude whether there was a significant treatment effect specifically for UMO. Future trials should be designed
to include quantitative measures of UMO as primary study outcomes, for example by reporting the presence or absence of UMO, or
by measuring central macular thickness for study participants. Furthermore, whilst UMO is an important complication of uveitis, we
acknowledge that uveitis is associated with many significant structural and functional complications. It is not possible to determine
treatment efficacy based on a single outcome measure. We recommend that future reviews of therapeutic interventions in uveitis should
use composite measures of treatment response comprising a range of potential complications of disease.
P L A I N L A N G U A G E S U M M A R Y
Anti-tumour necrosis factor medication for treating swelling at the back of the eye (macular oedema) due to inflammatory eye
disease (uveitis)
What is the aim of this review?
The aim of this Cochrane Review was to find out whether a new class of drugs (anti-tumour necrosis factor agents) is effective in treating
swelling at the back of the eye (macular oedema) caused by inflammation in the eye (uveitis). Cochrane Review authors searched for
all relevant studies to address this question, but found no suitable studies for inclusion.
Key messages
There is currently no evidence for or against the use of anti-tumour necrosis factor agents in treatment of macular oedema in uveitis.
What was studied in this review?
Uveitis is a group of eye conditions where there is inflammation within the eye. If there is inflammation at the back of the eye (macula)
this can cause swelling (macular oedema). Macula oedema can lead to loss of vision,
Uveitis is often treated with steroids to control the inflammation and avoid damage to the eye. But steroids have potentially serious side
effects, and doctors do not recommend long-term use. ’Steroid-sparing agents’ are medications with similar anti-inflammatory effects
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to steroids, but with fewer side effects. They are preferred when people with uveitis need long-term treatment. Anti-tumour necrosis
factor agents are a new type of steroid-sparing agent. They have been used for other conditions. Cochrane researchers wanted to find
out if these agents are useful in the treatment of macular oedema in uveitis.
What are the main results of the review?
Cochrane Review authors searched multiple electronic databases for studies of the use of anti-tumour necrosis factor medications
in macular oedema due to uveitis. They found no relevant studies. There are some studies that show that these drugs are effective
in controlling inflammation in the eye, but none of these specifically investigated macular oedema. More research is needed to help
informed decision-making in this area.
How up-to-date is this review?
Cochrane Review authors searched for studies that had been published up to 29 March 2018.
B A C K G R O U N D
Description of the condition
Uveitis describes a group of disorders characterised by intraocular
inflammation. Uveitis is the fifth most common cause of visual
loss in high-income countries, accounting for approximately 10%
to 15% of total blindness (Durrani 2004; William 2007). This
figure rises to 25% in low- andmiddle-income countries (Abdulaal
2015; Rao 2013). Although uveitis may affect any age group, it
peaks in theworking-age population,with no significant difference
between sexes (Acharya 2013). The annual incidence of uveitis is
estimated at 17.4 to 52.4 per 100,000 people with a prevalence
of around 38 to 114.5 per 100,000 general population (Durrani
2004; Gritz 2004; Suhler 2008; William 2007).
Uveitis often occurs in younger people in the working population
compared to other eye diseases such as cataracts and age-related
macular degeneration, so the condition has a huge impact in terms
of years of potential blindness and economic cost (Durrani 2004).
Uveitis may be classified anatomically as anterior uveitis, interme-
diate uveitis, posterior uveitis or pan-uveitis (Bloch-Michel 1987;
Deschenes 2008). It may arise from a range of different infectious
and non-infectious aetiological sources. The focus of this review
is non-infectious uveitis, most of which is thought to be auto-
immune (or at least auto-inflammatory) and usually requires im-
munosuppressive treatment (Barry 2014; VanGelder 1999). Non-
infectious uveitis may be associated with a range of inflammatory
syndromes, including ankylosing spondylitis, Behcet’s disease, sar-
coidosis and multiple sclerosis (Lee 2014a; Lee 2014b; Takeuchi
2013).
The leading cause of sight loss in people with uveitis is macular
oedema, known in this context as uveitic macular oedema (UMO)
(Durrani 2004; Lardenoye 2006). Macular oedema describes the
accumulation of fluid in the retina (the light-sensitive inner lining
of the eye) in the area that provides central vision known as the
’macula’ (Davis 2010; De Smet 2010). Macula oedema is more
common in forms of uveitis affecting the more posterior struc-
tures in the eye, namely intermediate and posterior uveitis and
pan-uveitis; collectively these are sometimes referred to as poste-
rior segment-involving uveitis. Macular oedema can also occur in
association with anterior uveitis (Kaiser 2009).
Macular oedema accounts for 41% of visual impairment and 29%
of blindness in uveitis (Levin 2014; Rothova 1996). The impact
of UMO on visual acuity is usually assessed using standard dis-
tance visual acuity charts, either a Snellen chart or an Early Treat-
ment Diabetic Retinopathy Study (ETDRS) chart. Acuities from
Snellen charts are usually reported in metres in the UK and feet in
the USA. Acuities from ETDRS charts are usually reported either
as ’number of letters read’ or converted into a LogMAR fraction.
Although certain visual acuities are considered to be equivalent
(e.g. 0.0 LogMAR = 6/6 UK Snellen = 20/20 US Snellen), these
equivalences are approximate due to intrinsic differences between
the charts (Kaiser 2009). Although the Snellen chart is still widely
used in clinical practice, most trials use ETDRS charts due to vari-
ousmethodological advantages. Traditionally,macular oedemahas
been assessed clinically using stereoscopic slit-lamp fundus bio-
microscopy and fluorescein angiography, an invasive procedure re-
quiring intravenous dye and stereo photography imaging testing
(Brown 2004). More recently a non-invasive imaging technique,
optical coherence tomography (OCT), has become a standard
clinical practice in monitoring treatment response and follow-up
of UMO (Karim 2013; Reinthal 2004). OCT may be more sen-
sitive than clinical measures in detecting the presence of UMO
and provides accurate measures of the structural changes in term
of macular thickness (Kempen 2013).
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Description of the intervention
There are a wide range of pharmacological treatments for UMO.
Corticosteroids are the mainstay of acute treatment (Davis 2010),
with alternative routes of administration including: systemic (oral,
intravenous and intramuscular); local, which includes periocu-
lar injection (sub-Tenon and orbital floor injection); and intraoc-
ular (intravitreal injection or implant) (Kok 2005; Venkatesh
2008). For long-term treatment it is important to reduce cor-
ticosteroid usage, leading to the use of ’second-line’ therapies,
which are typically immunomodulatory and include T-cell in-
hibitors (e.g. ciclosporin, and tacrolimus) and anti-metabolites
(e.g. azathioprine, methotrexate, mycophenolate mofetil). Alky-
lating agents (e.g. cyclophosphamide) have traditionally been used
as a ’third line’ for severe refractory disease (Barry 2014; Deuter
2009;Markomichelakis 2004; Neri 2008; Taylor 2009). Anti-vas-
cular endothelial growth factor (VEGF) agents and oral carbonic
anhydrase inhibitor (acetazolamide) have also occasionally been
used to treat UMO (Karim 2013). Anti-tumour necrosis factor
(anti-TNF) drugs (the subject of this Cochrane Review) have re-
cently been licensed for the treatment of uveitis (NICE 2017);
adalimumab has been approved as an option for treating non-in-
fectious uveitis in the posterior segment of the eye in adults in
cases of severe disease that demonstrates an inadequate response or
tolerance to immunosuppressant therapy. Historically, anti-TNF
agents have commonly been used off-licence, after the failure of
one or more second-line agents, but before the use of an alkylating
agent (Sharma 2009).
Anti-TNF drugs are biological agents that selectively block the
actions of TNF, a critical cell-signalling molecule (’cytokine’) in
the inflammatory process (Deuter 2009;McCluskey 2000). Orig-
inally pioneered in the 1990s for use in rheumatoid arthritis (RA),
anti-TNF drugs are now central to the treatment of many inflam-
matory diseases including RA, juvenile idiopathic arthritis, psori-
atic arthritis, ankylosing spondylitis (AS), Crohn’s disease (Sharma
2009), and Behcet’s disease (Hatemi 2008). As noted earlier, most
non-infectious uveitis is immune mediated and is commonly as-
sociated with many of these same systemic diseases (Lee 2014a;
Lee 2014b; Murphy 2004; Takeuchi 2013).
There are currently five anti-TNF agents licensed for a range of
non-ocular inflammatory diseases; none are licensed for ocular
inflammation (Scallon 1995; Scallon 2002). The first anti-TNF
agent to be developed for clinical use was infliximab, a chimeric
IgG1 that binds to soluble and membrane TNF-α, preventing
TNF-α frombinding to its receptor in the cell (Wooley 1995). The
main route of administration is intravenous (Markomichelakis
2004). The second anti-TNF agent to reach clinical usage was
etanercept. This is a soluble protein linked to the human Fc
fragment of IgG1 that prevents TNF-α and β from interacting
with their receptor; its route of administration is subcutaneous
(Jabs 2001). The third anti-TNF drug is adalimumab, which
is a humanised IgG monoclonal antibody that binds to human
TNF-α (Kaymakcalan 2009). Adalimumab is administered sub-
cutaneously (Rudwaleit 2009). In addition to direct effects on
the TNF-pathways, downstream effects appear to include an in-
crease of regulatory T cells and modulation of vascular endothelial
growth factor (VEGF)-mediated pathways (Erckens 2011).
Golimumab is a human monoclonal antibody to TNF-α with
the advantage of requiring only monthly subcutaneous injec-
tion (Cordero-Coma 2015; Feaz 2014; Miserocchi 2014). Cer-
tolizumab consists only of the pegylated humanised Fab fragment
of a monoclonal antibody directed against TNF-α. It is adminis-
tered subcutaneously once every two weeks (Sánchez-Cano 2013;
Tlucek 2012). Both agents have shown benefits for ocular inflam-
matory disease; however, existing data are limited to case reports
and case series (Mesquida 2013).
Although people with uveitis have received treatment with other
anti-TNFdrugs, themost commonly used anti-TNFagents are the
monoclonal antibodies infliximab and adalimumab; in addition to
the standard systemic administration, some authors have reported
intravitreal administration (Pascual-Camps 2014; Schaap-Fogler
2014). Some people with uveitis have also received other anti-
TNF drugs for uveitis.
How the intervention might work
The pathogenesis of the UMO is related to the underlying oc-
ular inflammatory process (uveitis) causing release of inflamma-
tory mediators including interleukin (IL)-1, IL-2, IL-6, IL-8,
and TNF-α, transforming growth factor (TGF)-β and interferon
(IFN)-γ , many of which directly or indirectly contribute to dis-
ruption of the blood-retina barrier. As a result, protein and large
molecules are trapped within the retina, causing fluid flow out
of the vessels via the osmotic gradient (Curnow 2006; Van Kooij
2006).
TNF-α, a key pro-inflammatory cytokine in a range of inflamma-
tory conditions, has proven pivotal in animal models of uveitis and
is present in intraocular fluids in human uveitis (Foxman 2002;
Murphy 2004). It is a pleiotropic cytokine produced by a number
of cells and has an important role in a range of leukocyte functions
(Feldmann 2005; Sfikakis 2004). Specific roles include: increas-
ing leukocyte recruitment to the eye via induction of chemokines
and increased leukocyte adhesion to vascular endothelium; den-
dritic cell maturation to increase the effectiveness of their antigen
presentation and cytokine production; macrophage activation and
enhancing T-cell activation. TNF-α may also be pro-apoptotic
for both infiltrating and resident cells (Cordero-Coma 2015). The
exact cascade of inflammatory mediators that leads to UMO is not
well understood (Curnow 2006; Schaap-Fogler 2014); however,
there is agreement that TNF-α upregulates VEGF production in
choroidal endothelial cells, andTNF-α blockade is associatedwith
a reduction in serum VEGF levels (Calleja 2012; Giraudo 1998;
Hangai 2006).
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Why it is important to do this review
UMO is the leading cause of sight loss in uveitis and a major cause
of blindness in the working-age population. There is mechanistic
data to support the proposal that anti-TNF drugs may provide
more targeted disease control of uveitis than provided by current
non-biological therapies, and there is evidence demonstrating sig-
nificant benefit of anti-TNF drugs in related systemic inflamma-
tory conditions. Off-licence use of anti-TNF agents for uveitis has
become common in some centres, but there is a lack of national
guidelines or consensus statements and considerable variation in
practice (Davis 2010; Karim2013; Sreekantam2011). This review
will assess the effects of the anti-TNF therapy in the management
of UMO. It is timely to review the literature in order to evaluate
and summarise the available evidence for anti-TNF therapy used
for the treatment of UMO, which may form the basis of evidence-
based clinical recommendations.
O B J E C T I V E S
To assess the effects of anti-TNF therapy for UMO.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include all relevant randomised controlled trials
(RCTs) assessing anti-TNF therapy for treating UMO.
Types of participants
We planned to include trials with participants of any age, sex or
ethnicity with a diagnosis of UMO.
Types of interventions
The primary comparisons of this review were:
• anti-TNF versus no treatment or placebo;
• anti-TNF versus another pharmacological agent;
• comparison of different anti-TNF drugs;
• comparison of different doses and routes of administration
of the same anti-TNF drug.
Types of outcome measures
We planned not to select studies based on outcomes. However,
we planned to consider clinical and patient-reported outcomes to
be important for the aims of the review. We planned to classify
outcomes as primary and secondary as follows.
Primary outcomes
The primary outcome measure for this review was best corrected
visual acuity (BCVA) in the treated eye. This was measured in the
following ways.
• Mean change in LogMAR BCVA between baseline (before
treatment) and at the pre-specified time points.
• The proportion of participants gaining 5 or more ETDRS
letters (equivalent to 1 ETDRS line or 0.1 LogMAR
improvement) at the follow-up visit in the treated eye at the pre-
specified time point.
• The proportion of participants losing 5 or more ETDRS
letters (equivalent to 1 ETDRS line or 0.1 LogMAR worsening)
recorded at the follow-up visit in the treated eye at the pre-
specified time point.
Secondary outcomes
Anatomical macular change
We planned to record anatomical changes in macular structure as
studies measured them.
• Mean change in central macular thickness (CMT) in
microns, as assessed by OCT at pre-specified time points.
• Proportion with clinical resolution of UMO, as assessed by
stereoscopic slit-lamp fundus biomicroscopy (clinical) at pre-
specified time points.
• Proportion with angiographic resolution of UMO, as
assessed by fundus fluorescein angiography at pre-specified time
points.
Clinical estimation of vitreous haze
• Changes in vitreous haze, as assessed by stereoscopic fundus
indirect biomicroscopy examination at pre-specified time points.
Health-related quality of life
• Mean change in quality-of-life score (both vision-related
and non-vision-related), as measured by any validated quality-of-
life questionnaire at the pre-specified time points
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Adverse events
• We planned to record all adverse events reported in the
included studies at the pre-specified time points.
We expected data to be available at multiple time points within
and between studies. We planned to categorise nominal data from
each analysis into three groups. We planned to group the postin-
tervention time points for assessment of outcomes into three dif-
ferent time ranges: 3 months or less; more than 3 months and up
to 6 months; and more than 6 months.
Search methods for identification of studies
Electronic searches
TheCochrane Eyes andVision Information Specialist searched the
following electronic databases for randomised controlled trials and
controlled clinical trials. There were no language or publication
year restrictions. The date of the search was 29 March 2018.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 3), which contains the Cochrane Eyes
and Vision Trials Register, in the Cochrane Library (latest issue)
(Appendix 1)
• MEDLINE Ovid (1946 to 29 March 2018) (Appendix 2)
• Embase Ovid (1947 to 29 March 2018) (Appendix 3)
• Web of Science Conference Proceedings Citation Index-
Science (CPCI-S) (1970 to 29 March 2018) (Appendix 4)
• System for Information on Grey Literature in Europe
(OpenGrey) ( www.opengrey.eu/ to 29 March 2018) (Appendix
5)
• ISRCTN registry ( www.isrctn.com/editAdvancedSearch;
searched 29 March 2018) 29 March 2018 (Appendix 6).
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( www.clinicaltrials.gov; searched 29 March
2018) (Appendix 7).
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( www.who.int/ictrp; searched
29 March 2018) (Appendix 8).
Searching other resources
We planned to search the reference lists of potentially relevant
studies to identify any additional trials. We did not handsearch
conference proceedings or journals for this review.
Data collection and analysis
Selection of studies
We carried out the study selection process in two stages.
• First, we screened the title and the abstract of identified
articles in order to remove irrelevant records, excluding articles
that obviously did not meet the selection criteria.
• Secondly, we planned to retrieve the full-text of any
potentially relevant articles and assess them against the selection
criteria.
At both stages, two review authors (MT and RB) independently
assessed articles, resolving any disagreements by discussion and if
required by referral to a third review author (DM). Two review au-
thors independently screened the titles and abstracts resulting from
the searches usingweb-based software Covidence (Covidence).We
have illustrated the study selection processes using a PRISMA flow
diagram (Moher 2010).
We planned to have non-English language articles translated in
part or in full to aid study selection and analysis.
As we did not identify any published RCTs for inclusion in our
review, we were not able to complete the steps for data extraction
or analysis. In future updates, if we find any RCTs that meet our
inclusion, we will follow the process outlined below.
Data extraction and management
See: Appendix 9
Two review authors (MT and RB) will extract data independently
using an online data extraction form in Covidence (Covidence).
We will resolve any discrepancies through discussion and referral
to a third review author (DM) if needed.Wewill use a standardised
piloted data extraction form. We may contact study authors for
further information. We will enter all data into Review Manager
5 (RevMan 5) software (Review Manager 2014). For each study,
we will extract at least the following information.
• Study characteristics
◦ Authors, publication year, title and journal
◦ Study design
◦ Setting
◦ Sample size
◦ Length of follow-up
◦ Analysis
• Participant characteristics
◦ Selection/recruitment criteria
◦ Demographic data; number, age, sex, socioeconomic
status and ethnicity
◦ Type of uveitis (anatomical categorisation, syndrome/
aetiological classification)
◦ Comorbidity
◦ Co-medication
• Intervention and comparator
◦ Pharmacological agents
◦ Regimen (dose, frequency of administration, route of
administration)
◦ Comparator details
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◦ Any difference in underlying care between treatment
groups
• Outcomes and findings
◦ Outcomes measured and results for each outcome
including precision and statistical test results
◦ Completeness of follow-up for each outcome
Assessment of risk of bias in included studies
Two review authors will independently assess the quality of in-
cluded studies, resolving disagreements through discussion and
referral to a third review author (DM) if required. We will employ
the methods set out in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Intervention (Higgins 2017).
We will consider the following domains.
• Selection bias: allocation concealment bias, randomisation
sequence generation bias
• Performance bias: masking (or blinding) of study
participants and the researcher
• Detection bias: masking (or blinding) of outcome assessors
• Attrition bias: loss to follow-up and rate of compliance in
both groups (withdrawals from the study lead to incomplete
outcome data)
• Reporting bias: selective outcome reporting
We will report the ’Risk of bias’ domains as being at low risk, high
risk or unclear risk (lack of information or uncertainty of potential
bias) (Higgins 2017). We will add data from the included studies
on risk of bias into Review Manager 2014.
Measures of treatment effect
Continuous data
We will report continuous variables as mean differences with their
corresponding 95% confidence intervals.
Dichotomous data
We will report dichotomous variables as risk ratios (RRs) with
their corresponding 95% confidence intervals.
We are likely to present results for some outcomes using a number
of differentmeasures/statistics measured within and between stud-
ies. For example, studies might report visual acuity in metres or
feet (from Snellen charts), a LogMAR score, or number of letters
or lines read (from ETDRS charts). Investigators may report the
change in acuity as a change in any one of these indices or cate-
gorised against a threshold, for example, proportion of participants
with change greater than or equal to a specific number of lines/
letters read (Kaiser 2009). Thus, different studies may consider
visual acuity to be continuous data (e.g. group mean LogMAR
score), discrete data (e.g. number of lines read) or dichotomous
data (e.g. proportion of participants reading x lines, or proportion
with a LogMAR score greater than y). it is likely that continuous
and dichotomous data will be most common. We will consider
converting data between formats to maximise the data available
for each analysis (for example, if authors state the type of chart,
we might convert letters into lines; interchange LogMAR score
and letters; and approximate Snellen UK, US and ETDRS data).
We will undertake any conversion of data with due caution, tak-
ing into account known issues (Kaiser 2009). We will explicitly
acknowledge the impact of any converted data on findings and
explore this aspect through sensitivity analysis.
We will also analyse secondary outcome measures, presenting
CMT as mean difference with 95% confidence intervals. We will
pool health-related quality of life from the same scales using mean
difference, and when studies use different scales to assess the same
underlying concepts/domains, we will use standardised mean dif-
ference.
For adverse events reported in the included studies, we will record
counts and rates. We may consider these data as continuous if the
adverse events are common and occur often (presented as mean
difference) or dichotomous data if the adverse events occur rarely
(presented as rate ratio).
Unit of analysis issues
Clinical trials in ophthalmology may randomise one or both eyes
of participants to the intervention. The unit of randomisationmay
depend on the intervention.
• If the intervention is systemic (IV or SC) then the unit of
randomisation in the studies will be the participant.
• If the intervention is intraocular - then the unit of
randomisation could be the participant or the eye.
The unit of analysis might also depend on the outcome.
• For most outcomes related to vision, our primary unit of
analysis will be the eye.
• For outcomes related to things like quality of life, the unit
of analysis will be the participant.
• For adverse events, the unit of analysis will be the
participant (and/or the eye in case of intraocular administration).
If studies include only one eye from each participant, the unit
of analysis can either be the eye or the person. If two eyes from
each participant receive the same intervention, and study authors
report them as a single unit (either through only one eye used in
analysis, or as the average outcome for the two eyes), then the unit
of analysis will be the participant.
If studies include two eyes per participant, with no differences in
treatment between eyes, and they analyse them as two eyes, the
outcome in each eye is likely to be more similar to the outcome in
the companion eye than the eye of a different participant; therefore
the study design could/should be considered as comparable to a
cluster-randomised study.
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If the intervention is intraocular administration, and participants
receive different treatments in each eye (e.g. paired-eye/within-
person design), we can compare outcomes between the two eyes
and assess within-person differences if data are available. However,
if the study includes more than one eye from some participants
but not all participants, and the unit of analysis is the eye, then
we should record this, as there are issues with unit of analysis that
may not be resolvable. There are inadequate data available to know
whether the intravitreal injection of anti-TNF agents may result
in therapeutically significant systemic levels. On this basis, we will
include anywithin-person (paired-eye) studies for intravitreal anti-
TNF but report them separately.
Dealing with missing data
We will assess all the included studies for number of participants
excluded or lost to follow-up. For unclear or missing required in-
formation in study reports (e.g. on features such as study meth-
ods, outcome data, and measures of data variation), we will con-
tact study authors. However, if the study authors do not respond
within four weeks or are not able to provide the additional data,
we will conduct analyses based on the best available information.
We will identify the distribution of missing data between the two
arms and discuss the potential impact of missing data on the find-
ings of the review.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity to deter-
mine whether studies are sufficiently similar for each comparison/
outcome to ensure that data pooling by meta-analysis is appropri-
ate (Higgins 2002; Huedo-Medina 2006). If we combine studies
in a meta-analysis, where appropriate we will report the I2 statistic
(Higgins 2003), which gives the percentage of the total variabil-
ity in the data due to between-study heterogeneity, and the Tau
2 statistic, which gives an estimate of the between-study variance
(Higgins 2017).
Assessment of reporting biases
We will examine selective outcome reporting by comparing out-
comes reported in included studies and the outcomes recorded
in study protocols. If the protocols are not publicly available, we
will contact study authors to supply them. For each meta-analysis
containing 10 or more studies, we will construct a funnel plot and
assess asymmetry in the plotted data (Peters 2008). Any asymme-
try may imply possible publication bias, poor reporting of small
studies, true heterogeneity or chance.
Data synthesis
Wewill assess the consistency of clinical andmethodological study
characteristics, and if there is no substantial heterogeneity between
the trials, we will combine results in a meta-analysis using a ran-
dom-effects model. If there is substantial clinical or statistical het-
erogeneity, we will not combine study results in meta-analysis but
will present data in a narrative summary.
Subgroup analysis and investigation of heterogeneity
We will consider subgroup analysis for clinical and anatomical
classification of uveitis (anterior, intermediate, posterior and pan-
uveitis) where deemed appropriate.
Sensitivity analysis
We will perform sensitivity analysis to assess the robustness of the
results and the effect of excluding trials judged to have a high risk
of bias in one or more domains.
’Summary of findings’ table and GRADE
If sufficient data are available, wewill produce a ’Summary of find-
ings’ table for outcomes at six months’ follow-up to provide key
information concerning the quality of evidence, the magnitude of
effect of the interventions examined, and the sum of available data
on all of the primary and secondary outcomes for a given com-
parison. Two review authors will independently use the GRADE
tool to assess the certainty of the evidence in the included studies
(GRADEpro GDT). The GRADE system entails an assessment
of the quality of a body of evidence for each individual outcome.
We will resolve any discrepancies by discussion and refer to a third
review author if needed. The table of results will include the pri-
mary outcome for the review, which will be the BCVA, using ei-
ther the mean change in LogMAR BCVA from baseline at the pre-
specified time point or the proportion of participants gaining 5 or
more ETDRS letters from baseline BCVA. In addition, the tables
will include results for the following outcomes.
• Mean change in CMT from the baseline at the pre-specified
time point
• Proportion of eyes with absence of dye leakage on
fluorescein angiography
• Mean change in vitreous haze from the baseline
• Mean change in quality-of-life score
• Proportion of participants with adverse events
R E S U L T S
Description of studies
Results of the search
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The electronic searches yielded 423 records (Figure 1). The
Cochrane Information Specialist removed 81 duplicate records
and we screened the remaining 342 reports for potential inclu-
sion in the review. We obtained two full-text reports for further
assessment, however these did not meet the inclusion criteria, see
Characteristics of excluded studies for details. We did not identify
any ongoing studies from searches of the trials registers.
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Figure 1. Study flow diagram
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Included studies
We found no studies that met the inclusion criteria for this review.
Excluded studies
We excluded two studies on patients with uveitis because they did
not report relevant outcomes separately for any participants with
UMO (Jaffe 2016; Nguyen 2016).
Risk of bias in included studies
We found no studies that met the inclusion criteria for this review.
Effects of interventions
We found no studies that met the inclusion criteria for this review.
D I S C U S S I O N
Summary of main results
We conducted a search of several electronic literature databases to
identify randomised or quasi-randomised trials that evaluated the
role of anti-TNF therapy in the management of UMO. Despite
using a sensitive search strategy, we did not identify any such trials.
Our search highlighted the lack of rigorous evidence to guide
the use of anti-TNF therapy in the management of UMO, and
identifies a need for further work in this area.
Overall completeness and applicability of
evidence
Treatment of non-infectious uveitis necessitates titration of anti-
inflammatory agents in order to achieve suppression of the in-
tra-ocular inflammatory response. There are no universally ac-
cepted guidelines for disease management, and a wide range of
immunomodulatory agents have been suggested as having benefi-
cial effects in controlling disease (Barry 2014). Anti-TNF agents
have emerged as a promising treatment modality, with mechanis-
tic data to suggest that they may offer more targeted treatment of
intraocular inflammation than existing non-biologic, steroid-spar-
ing agents.Off-licence use of anti-TNF agents for uveitis has previ-
ously been widely reported (Davis 2010; Karim 2013; Sreekantam
2011), and following the recent publication of the National Insti-
tute for Health and Care Excellence (NICE) guidelines, the use of
adalimumab in resistant disease is now standard practice through-
out the UK (NICE 2017).
To date, there have been two large-scale, placebo-controlled, ran-
domised controlled trials investigating the effect of adalimumab in
non-infectious intermediate, posterior or pan-uveitis (Jaffe 2016;
Nguyen 2016). In both studies, control of inflammation was first
achieved with systemic corticosteroid treatment, before partici-
pants were randomised to receive either adalimumab by subcu-
taneous injection or placebo. The primary outcome was time to
treatment failure, defined by a multicomponent endpoint includ-
ing the occurrence of new inflammatory lesions in the retina,
BCVA, anterior chamber cell grade, and vitreous haze grade. Both
studies concluded that adalimumab significantly lowered the risk
of uveitic flare or loss of visual acuity upon corticosteroid with-
drawal in people with inactive, non-infectious intermediate, pos-
terior, or pan-uveitic uveitis controlled by systemic corticosteroids.
Since both studies reported time to treatment failure as the pri-
mary outcome, neither were suitable for inclusion in this review.
Furthermore, neither study reported subgroup analysis of resolu-
tion or development of UMO, and we are therefore unable to
comment whether adalimumab provides specific treatment bene-
fit in this area.
Quality of the evidence
We did not identify any trials for inclusion in this review.
Potential biases in the review process
We aimed to minimise potential biases in the review process by
conducting a highly sensitive search for trials, and following rig-
orous methods as recommended by Cochrane (Lefebvre 2011).
Agreements and disagreements with other
studies or reviews
A few non-randomised studies supported the use of anti-TNF
agents in the treatment of UMO. However, we did not include
such studies in this review, and have not conducted a comprehen-
sive search and critical appraisal of evidence from non-randomised
studies.
In a retrospective review of patients with macular oedema sec-
ondary to birdshot chorioretinopathy, Steeples 2017 demonstrated
adalimumab to be effective in reducing CMT over a 12-month
period. Calvo-Rio 2014 demonstrated a similar beneficial effect
of adalimumab in a cohort of patients with refractory macular
oedema secondary to Behcet’s Disease. Schaap-Fogler 2014 re-
ported outcomes of adalimumab in adults with macular oedema
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due to non-infectious uveitis of varying aetiologies, suggesting that
maximum improvement in CMT was observed at six months,
however the treatment effect had lessened by 12 months’ follow-
up, whilst Markomichelakis 2004 demonstrated an improvement
in CMT with infliximab therapy, which was maintained to six
months’ follow-up.
In summary, whilst these non-randomised reviews suggest that
anti-TNF therapy is indeed effective in the treatment of UMO,
they do not provide definitive evidence of treatment benefit.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Uveiticmacular oedema (UMO) remains a blindingmanifestation
of ocular inflammatory disease. Preservation of visual function is
dependent on achieving rapid disease control, with early restora-
tion of macular anatomy in an attempt to avoid irreversible loss of
photoreceptors in this area. Whilst the aetiology of uveitis remains
unknown in the majority of cases, the mainstay of treatment re-
mains suppression of the intra-ocular immune system; unfortu-
nately this necessitates systemic immune suppression inmost cases,
and thus there is a need to identify targeted treatment modalities
to avoid unwanted systemic effects. Anti-tumour necrosis factor
(TNF) agents have been demonstrated to be well-tolerated and
highly effective in the management of uveitis (Jaffe 2016; Nguyen
2016), such that adalimumab is now licensed for this purpose in
the UK (NICE 2017). Adalimumab is currently licensed for use
as a third-line agent, following development of tolerance or fail-
ure to respond to second-line, steroid-sparing agents; it is unclear
whether earlier introduction of anti-TNF agents would confer ad-
ditional benefit in management of UMO and preservation of vi-
sual function.
Implications for research
Our systematic review demonstrates the need for high-quality, ran-
domised controlled trials (RCTs) to determine the role of anti-
TNF agents in UMO. Adalimumab is already licensed for use in
uveitis and its efficacy has been assessed through RCTs. Unfor-
tunately published data reports time-to-treatment-failure analyses
(Jaffe 2016; Nguyen 2016), and does not specifically address de-
velopment of UMO, or resolution of UMO in uveitic patients us-
ing anti-TNF therapy.With the widespread use of retinal imaging,
it would be relatively easy to include CMT (measured by optical
coherence tomography (OCT)), or presence/absence of macular
oedema (measured by OCT, OCT-angiography or fundus fluo-
rescein angiography) to future studies to enable us to address this
important question.
We also acknowledge that whilst UMO is an important compli-
cation of disease, uveitis is associated with many significant struc-
tural and functional complications. In clinical practice, treatment
efficacy is determined with reference to the full range of disease
complications experienced by the patient. Making management
decisions with consideration of only a single outcome measure
may miss important treatment effects on other disease manifesta-
tions. We therefore recommend that future reviews of therapeutic
interventions in uveitis should use composite measures of treat-
ment response comprising a range of potential complications of
disease.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 [mh “Macular Edema”]
#2 [mh “Macula Lutea”]
#3 macula* near/3 oedema
#4 macula* near/3 edema
#5 UMO
#6 maculopath*
#7#1 or #2 or #3 or #4 or #5 or #6
#8 [mh uveitis]
#9 uveiti*
#10 iritis
#11 iridocycliti*
#12 anterior near/2 scleriti*
#13 pars planitis
#14 retinochoroidit* or choroidit*
#15 Bechet* or Vogt or Koyanagi or Harada or Fuch*
#16 [mh retinitis]
#17 retinitis or neuroretinitis
#18 uveoretinitis or uveo retinitis
#19 vitritis or panuveitis or panophthalmiti*
#20 ophthalm* near/2 sympathetic
#21 [mh “arthritis juvenile rheumatoid”]
#22 juvenile near/2 rheumatoid near/2 arthriti*
#23 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 [mh ˆ“Tumor Necrosis Factor-alpha”]
#25 [mh ˆ“Antibodies, Monoclonal”]
#26 [mh ˆ“Antibodies, Monoclonal, Humanized”]
#27 [mh Înfliximab]
#28 [mh Âdalimumab]
#29 [mh Êtanercept]
#30 [mh ˆ“Certolizumab Pegol”]
#31 remicade* or humira* or enbrel* or golimuab* or simponi* or cimzia*
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#32 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
#33 #7 and #23 and #32
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. (group or groups).ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. Macular Edema/
14. Macula Lutea/
15. (macula$ adj3 oedema).tw.
16. (macula$ adj3 edema).tw.
17. UMO.tw.
18. maculopath$.tw.
19. or/13-18
20. exp uveitis/
21. uveiti$.tw.
22. iritis.tw.
23. iridocycliti$.tw.
24. (anterior adj2 scleriti$).tw.
25. pars planitis.tw.
26. (retinochoroidit$ or choroidit$).tw.
27. (Bechet$ or Vogt or Koyanagi or Harada or Fuch$).tw.
28. exp retinitis/
29. (retinitis or neuroretinitis).tw.
30. (uveoretinitis or uveo retinitis).tw.
31. (vitritis or panuveitis or panophthalmiti$).tw.
32. (ophthalm$ adj2 sympathetic).tw.
33. arthritis juvenile rheumatoid/
34. (juvenile adj2 rheumatoid adj2 arthriti$).tw.
35. or/20-34
36. Tumor Necrosis Factor-alpha/
37. Antibodies, Monoclonal/
38. Antibodies, Monoclonal, Humanized/
39. Infliximab/
40. Adalimumab/
41. Etanercept/
42. Certolizumab Pegol/
43. (remicade$ or humira$ or enbrel$ or golimuab$ or simponi$ or cimzia$).tw.
44. or/36-43
45. 19 and 35 and 44
46. 12 and 45
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
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Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula edema/
34. eye edema/
35. (macula$ adj3 oedema).tw.
36. (macula$ adj3 edema).tw.
37. UMO.tw.
38. maculopath$.tw.
39. or/33-38
40. exp eye inflammation/
41. uveiti$.tw.
42. iritis.tw.
43. iridocycliti$.tw.
44. (anterior adj2 scleriti$).tw.
45. pars planitis.tw.
46. (retinochoroidit$ or choroidit$).tw.
47. (Bechet$ or Vogt or Koyanagi or Harada or Fuch$).tw.
48. (retinitis or neuroretinitis).tw.
49. (uveoretinitis or uveo retinitis).tw.
50. (vitritis or panuveitis or panophthalmiti$).tw.
51. (ophthalm$ adj2 sympathetic).tw.
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52. arthritis juvenile rheumatoid/
53. (juvenile adj2 rheumatoid adj2 arthriti$).tw.
54. or/40-53
55. exp tumor necrosis factor alpha/
56. antibodies, monoclonal, humanized/
57. monoclonal antibody/
58. Infliximab/
59. Adalimumab/
60. Etanercept/
61. Certolizumab Pegol/
62. (remicade$ or humira$ or enbrel$ or golimuab$ or simponi$ or cimzia$).tw.
63. or/55-62
64. 39 and 54 and 63
65. 32 and 64
Appendix 4. Web of Science CPCI search strategy
#10 #9 AND #8 AND #3
#9 TS=(Infliximab OR Adalimumab OR Etanercept OR Certolizumab NEAR/1 Pegol OR remicade* OR humira* OR enbrel* OR
golimuab* OR simponi* OR cimzia*)
#8 #4 OR #5 OR #6 OR #7
#7 TS=(vitritis OR panuveitis OR panophthalmiti* OR ophthalm* NEAR/2 sympathetic OR juvenile NEAR/2 rheumatoid NEAR/
2 arthriti*)
#6 TS=(retinochoroidit* OR choroidit* OR Bechet* OR Vogt OR Koyanagi OR Harada OR Fuch* OR retinitis OR neuroretinitis
OR uveoretinitis OR uveo NEAR/1 retinitis)
#5 TS=(pars NEAR/1 planitis OR anterior NEAR/2 scleriti*)
#4 TS=(uveiti* OR iritis OR iridocycliti*)
#3 #1 OR #2
#2 TS=(UMO OR maculopath*)
#1 TS=(macula* NEAR/3 oedema OR macula* NEAR/3 edema OR macula* NEAR/3 lutea)
Appendix 5. OpenGrey search strategy
(macular oedema OR uveitis) AND (infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab)
Appendix 6. ISRCTN search strategy
“( Condition: macular oedema OR uveitis AND Interventions: infliximab OR adalimumab OR etanercept OR golimumab OR
certolizumab )”
Appendix 7. ClinicalTrials.gov search strategy
macula edema OR uveitis | (infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab)
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Appendix 8. WHO ICTRP search strategy
macular oedema OR uveitis = CONDITION AND infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab =
INTERVENTION
Appendix 9. Data on study characteristics
Mandatory items Optional items
Methods
Study design · Parallel-group RCT i.e. people ran-
domised to treatment
· Within-person RCT i.e. eyes randomised
to treatment
·Cluster-RCT i.e. communities randomised
to treatment
· Cross-over RCT
· Other, specify
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
How were missing data handled? e.g. avail-
able-case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
Unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within-person correlation/both
and not adjusted for within-person correla-
tion) and specify if mixture one eye and two
eye
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
Country Setting
Ethnic group
Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are reported for the people whowere
followed up only, please indicate.
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
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(Continued)
Intervention (n = )
Comparator (n = )
See MECIR 65 and 70
· Number of people randomised to this
group
· Drug (or intervention) name
· Dose
· Frequency
· Route of administration
Outcomes
Primary and secondary outcomes as defined
in study reports
See MECIR R70
List outcomes
Adverse events reported (Y/N)
Length of follow-up and intervals at which
outcomes assessed
Planned/actual length of follow-up
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Reported subgroup analyses (Y/N)
Were trial investigators contacted?
Sources of funding
Declaration of interest
See MECIR 69
C O N T R I B U T I O N S O F A U T H O R S
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and reviewed all papers identified in the database search and drafted the review text. All review authors read and approved the final
manuscript.
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